(19)
(11) EP 3 271 389 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
22.04.2020 Bulletin 2020/17

(45) Mention of the grant of the patent:
12.02.2020 Bulletin 2020/07

(21) Application number: 16716979.6

(22) Date of filing: 18.03.2016
(51) International Patent Classification (IPC): 
C07K 16/10(2006.01)
A61P 31/18(2006.01)
(86) International application number:
PCT/US2016/023145
(87) International publication number:
WO 2016/154003 (29.09.2016 Gazette 2016/39)

(54)

NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE

NEUTRALISIERENDE ANTIKÖRPER GEGEN GP120 UND DEREN VERWENDUNG

ANTICORPS NEUTRALISANTS DIRIGÉS CONTRE GP120 ET UTILISATION DE CEUX-CI


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 20.03.2015 US 201562136228 P
03.11.2015 US 201562250378 P

(43) Date of publication of application:
24.01.2018 Bulletin 2018/04

(60) Divisional application:
20156388.9

(73) Proprietor: The United States of America, as represented by the Secretary, Department of Health and Human Services
Bethesda, MD 20852-7660 (US)

(72) Inventors:
  • CONNORS, Mark
    Bethesda, MD 20814 (US)
  • HUANG, Jinghe
    Bethesda, MD 20892 (US)
  • KANG, Byong, Ha
    Bethesda, MD 20814 (US)
  • MASCOLA, John
    Bethesda, MD 20892 (US)
  • ISHIDA, Elise
    Bethesda, MD 20892 (US)
  • ZHOU, Tongqing
    Bethesda, MD 20892 (US)
  • KWONG, Peter
    Bethesda, MD 20892 (US)
  • ZHENG, Anqi
    Bethesda, MD 20892 (US)

(74) Representative: Gowshall, Jonathan Vallance 
Forresters IP LLP Skygarden Erika-Mann-Strasse 11
80636 München
80636 München (DE)


(56) References cited: : 
WO-A1-2012/154312
WO-A1-2013/163427
   
  • XUELING WU ET AL: "Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 329, no. 5993, 13 August 2010 (2010-08-13), pages 856-861, XP002669441, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1187659 [retrieved on 2010-07-08]
  • MCKAY BROWN ET AL: "Tolerance to single, but not multiple, amino acid replacements in antibody V-H CDR2: A means of minimizing B cell wastage from somatic hypermutation?", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 156, no. 9, 1 January 1996 (1996-01-01), pages 3285-3291, XP002649029, ISSN: 0022-1767
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).